{"url_path":"/sec/inkt/8-k/2026-05-15/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1840229/0001193125-26-225369-index.html","accession_number":"0001193125-26-225369","cik":"0001840229","ticker":"INKT","issuer_name":"MiNK Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1840229/0001193125-26-225369-index.html","primary_entity_key":"0001840229","primary_entity_name":"MiNK Therapeutics, Inc."},"word_count":124,"has_tables":true,"body_markdown":"## Item 2.02 Results of Operations and Financial Condition.\n\nOn May 15, 2026, MiNK Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026. In connection with the announcement, the Company issued a press release, which is being furnished as Exhibit 99.1 to this current report on Form 8-K.\n\nThe information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as expressly set forth by specific reference in such filing."}